• TRPV1+ Nerve Stimulation Suppresses Inflammation via Neural

  2026-06-19

  This study demonstrates that targeted stimulation of TRPV1+ peripheral somatosensory nerves induces a somato-autonomic reflex that robustly suppresses systemic inflammation. The findings reveal a neuro-immune circuit linking sensory nerve activation with anti-inflammatory outcomes, providing mechanistic insight and translational avenues for modulating immune responses.

• SCH772984 HCl: Precision ERK1/2 Inhibition in Telomerase Res

  2026-06-18

  Explore the unique value of SCH772984 HCl as a potent ERK1/2 inhibitor for dissecting MAPK pathway regulation of telomerase and overcoming resistance in BRAF- and RAS-mutant cancers. This article reveals advanced insights for translational cancer and stem cell research.

• Biotin-HPDP: Precision Thiol-Specific Protein Biotinylation

  2026-06-18

  Biotin-HPDP empowers researchers with selective, reversible thiol labeling for advanced protein biotinylation and affinity purification. Explore experimental workflows, troubleshooting strategies, and the latest cancer immunology applications that set this reagent apart.

• Cholesterol Impedes Intracellular Trafficking of Lipid Nanop

  2026-06-17

  This study presents a mechanistic analysis of how cholesterol content within lipid nanoparticles disrupts their intracellular trafficking, specifically by inducing aggregation in peripheral early endosomes and reducing nucleic acid delivery efficiency. The findings have practical implications for optimizing LNP formulations in nucleic acid therapeutics and underscore the utility of high-sensitivity fluorescent detection platforms.

• SGI-1027: DNA Methyltransferase Inhibitor for Cancer Epigene

  2026-06-17

  SGI-1027 stands out as a robust DNA methyltransferase inhibitor, enabling rapid, reliable demethylation and tumor suppressor gene reactivation in cancer research. Its dual mechanism—competitive inhibition and selective DNMT1 degradation—offers unique advantages for epigenetic modulation, with streamlined workflows and actionable troubleshooting insights tailored for demanding in vitro experiments.

• Cabozantinib (XL184): Protocol Advances in RCC Signaling Res

  2026-06-16

  Cabozantinib (XL184) enables dynamic modeling of kinase inhibition and adaptive signaling in renal cell carcinoma. This guide delivers stepwise workflow optimizations, advanced troubleshooting, and data-driven assay enhancements rooted in the latest phosphoproteomic research.

• Phosphatase Inhibitor Cocktail 1: Reliable Protein Phosphory

  2026-06-16

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) sets the standard for robust protein phosphorylation preservation in cell and tissue lysates, enabling uncompromised phosphoproteomic and signaling pathway analysis. Discover practical protocol enhancements, troubleshooting insights, and how this APExBIO solution empowers translational research from cardiac models to advanced biochemical assays.

• AGO1’s RNA-Independent Role in Stem Cell Fate via Protein Fo

  2026-06-15

  Liu et al. reveal that AGO1 promotes stemness in mouse embryonic stem cells by facilitating protein folding through HOP, independently of small RNA binding. This finding redefines Argonaute protein functions and provides new mechanistic insight for pluripotency and differentiation research.

• Z-DEVD-FMK: Dual Caspase-Calpain Inhibition for Translationa

  2026-06-15

  Explore how Z-DEVD-FMK, a potent caspase-3 inhibitor, reshapes translational research by bridging mechanistic clarity with dual-pathway inhibition—enabling rigorous dissection of apoptosis, necrosis, and neuroprotection. With new insights into caspase-driven cell death and emerging intersections with pyroptosis, this article offers a strategic, evidence-based roadmap for deploying Z-DEVD-FMK in the next generation of apoptosis assays and brain injury models.

• GI 254023X: Selective ADAM10 Inhibitor for Vascular & Cell M

  2026-06-14

  GI 254023X delivers nanomolar precision as a selective ADAM10 inhibitor, uniquely enabling apoptosis induction in Jurkat cells and protection against Staphylococcus aureus α-hemolysin in endothelial models. Explore stepwise protocols, troubleshooting, and translational strategies to leverage its high selectivity and robust performance in complex disease-relevant assays.

• Torin2 in Cancer Research: Precision mTOR Inhibition and Ass

  2026-06-13

  Explore how Torin2, a potent mTOR inhibitor, is revolutionizing cancer research through detailed mechanistic action, advanced in vitro assay design, and practical protocol guidance. This article offers unique insights into Torin2's selectivity and real-world applications.

• Essential Fe–S Cluster in DNA Polymerase ε Catalytic Core: S

  2026-06-12

  This study provides direct structural evidence for a single iron–sulfur (Fe–S) cluster in the catalytic core (Pol2CORE) of DNA polymerase ε, demonstrating its essential role in polymerase activity and cell viability. These findings clarify a longstanding debate regarding Fe–S cluster localization and function in eukaryotic replicative polymerases, with significant implications for understanding genome replication fidelity.

• DiscoveryProbe™ Metabolism-related Compound Library: Technic

  2026-06-12

  The DiscoveryProbe™ Metabolism-related Compound Library addresses the need for high-quality, functionally diverse small molecules to interrogate metabolic pathways and enzyme targets in vitro and ex vivo. It enables reproducible metabolic enzyme inhibition assays and pathway modulation, but is not suitable for diagnostic or clinical applications.

• Vemurafenib (PLX4032, RG7204): Reliable Workflows for Melano

  2026-06-11

  This article delivers scenario-driven, evidence-backed guidance for researchers applying Vemurafenib (PLX4032, RG7204) (SKU A3004) in cell viability and tumor regression assays. It addresses practical laboratory challenges, protocol optimization, and resistance analysis, with insights grounded in both product data and peer-reviewed studies. APExBIO’s Vemurafenib (A3004) is highlighted for its reproducibility and compatibility within advanced cancer biology workflows.

• ORAI2-Mediated SOCE Drives Early Salivary Gland Fibrosis Pos

  2026-06-11

  This study identifies ORAI2 as a pivotal regulator of early-stage postirradiation fibrosis in salivary glands, acting through a newly defined ORAI2/JNK/NFAT1/TGF-β1 axis. Pharmacological inhibition of SOCE and NFAT1 mitigated fibrosis and restored gland function, offering new molecular targets for intervention.

17017 records 5/1135 page Previous Next 12345 下5页 Last page